1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

Updated DMF Guidance Reflects GDUFA II

Draft FDA Guidance Also Requires Electronic Submission

 
• By Joanne S. Eglovitch

US FDA’s first revision of its foundational Drug Master Files guidance in 30 years contains few surprises but incorporates statutory and regulatory actions. Among the changes: a new section requiring electronic submission of DMFs and a section reflecting GDUFA II completeness assessments in Type II DMFs.

PS1910_Confidential-letter_1109454380_1200.jpg
FDA's Draft DMF Revision Reflects New Laws And Policies • Source: Shutterstock

The US Food and Drug Administration has revised its guidance on Drug Master Files, its first in 30 years, and the new update reflects the statutory and regulatory actions since 1989 that affect DMF policy. For example, the revision adds a new section governing the electronic submissions of DMFs as well as a new section on Type II DMFs reflecting the Generic Drug User Fee Amendments of 2012.

GDUFA II requires Type II DMF holders to submit “completeness assessments” before reviews on abbreviated new drug applications can begin. It also includes more detail on what should go in...

More from Regulation

Regulatory Recap: ICH To Determine The Future Of Biosimilar Comparative Efficacy Studies

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

More from Policy & Regulation